Brokerages predict that Stryker Co. (NYSE:SYK) will announce $1.68 earnings per share for the current quarter, according to Zacks. Eleven analysts have issued estimates for Stryker’s earnings, with estimates ranging from $1.66 to $1.70. Stryker reported earnings of $1.52 per share during the same quarter last year, which would indicate a positive year over year growth rate of 10.5%. The company is expected to issue its next earnings results on Thursday, October 25th.

According to Zacks, analysts expect that Stryker will report full year earnings of $7.25 per share for the current fiscal year, with EPS estimates ranging from $7.23 to $7.27. For the next year, analysts expect that the firm will post earnings of $7.97 per share, with EPS estimates ranging from $7.89 to $8.08. Zacks’ EPS calculations are an average based on a survey of analysts that cover Stryker.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 24th. The medical technology company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.73 by $0.03. The company had revenue of $3.32 billion during the quarter, compared to analysts’ expectations of $3.31 billion. Stryker had a net margin of 8.28% and a return on equity of 26.93%. Stryker’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.53 earnings per share.

Several brokerages recently commented on SYK. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $196.00 price objective for the company in a research note on Friday, June 1st. BMO Capital Markets reaffirmed a “hold” rating and set a $174.00 price objective on shares of Stryker in a research note on Thursday, July 12th. Royal Bank of Canada reaffirmed a “buy” rating and set a $184.00 price objective on shares of Stryker in a research note on Wednesday, July 25th. Canaccord Genuity reaffirmed a “buy” rating and set a $185.00 price objective on shares of Stryker in a research note on Wednesday, July 25th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research note on Wednesday, July 25th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $177.25.

Shares of NYSE:SYK opened at $169.02 on Tuesday. The company has a market cap of $63.76 billion, a P/E ratio of 26.04, a PEG ratio of 2.39 and a beta of 0.62. Stryker has a 12 month low of $138.56 and a 12 month high of $179.84. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.83 and a quick ratio of 1.15.

A number of institutional investors have recently made changes to their positions in SYK. Atlantic Trust LLC bought a new stake in shares of Stryker in the 2nd quarter worth approximately $105,000. Centaurus Financial Inc. bought a new stake in shares of Stryker in the 2nd quarter worth approximately $110,000. Kaizen Advisory LLC lifted its holdings in shares of Stryker by 142.6% in the 2nd quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock worth $127,000 after acquiring an additional 442 shares during the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of Stryker in the 2nd quarter worth approximately $135,000. Finally, CX Institutional bought a new stake in shares of Stryker in the 2nd quarter worth approximately $133,000. Institutional investors and hedge funds own 75.12% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Market Capitalization – What it Means for Investors

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.